相关实验视频
Updated: Jul 21, 2025

08:23
Assessing Burrowing, Nest Construction, and Hoarding in Mice
Published on: January 5, 2012
32.2K
评估COVID-19封锁对早期阿尔茨海默病进展的影响
Carmen Peña-Bautista1, Lourdes Álvarez-Sánchez1, Inés Ferrer-Cairols1
1Alzheimer's Disease Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Journal of neurology
|July 28, 2023
概括
由于COVID-19的封锁,阿尔茨海默氏症早期的认知衰退并没有加速.
科学领域:
- 神经学 神经学
- 老年学是指老年学的学科.
- 流行病学 流行病学
背景情况:
- COVID-19大流行大大改变了日常生活,可能会影响像阿尔茨海默病 (AD) 患者这样的弱势群体.
- 锁定期间减少社交接触和认知刺激可能会影响AD表达和残疾进展.
研究的目的:
- 调查COVID-19封锁对阿尔茨海默病早期患者认知障碍进展的影响.
主要方法:
- 对患有轻度认知障碍因AD (MCI-AD) 的患者,在两年内进行了两次神经心理评估 (认知和日常活动测试).
- 参与者被分为一个病例组 (在锁定前和之后进行评估) 和一个控制组 (在锁定前完全进行评估).
主要成果:
- 所有参与者在两年内都表现出增加的认知障碍和功能恶化.
- 由于COVID-19封锁,没有观察到认知障碍的加速恶化.
- 在封锁期间评估的病例组,与对照组相比,日常生活活动的恶化甚至更小.
结论:
- 在中期 (2年) 评估期内,COVID-19封锁并没有加速MCI-AD患者的认知衰退.
- 在封锁组中观察到的日常生活活动的较小下降可能归因于日常变化.
- 该研究没有证明因锁定而加速AD进展,但需要进一步的长期研究.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.5K
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
19.2K
相关概念视频
Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Cognitive Development During Adulthood
159
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
159